Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996812 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia
A Phase 1 study of Hyperinsulinemia Hypoglycemia, sponsored by Tracey McLaughlin.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02996812: Completed Phase 1 study of Hyperinsulinemia Hypoglycemia, sponsored by Tracey McLaughlin.
NCT02996812 is a Phase 1 study of Hyperinsulinemia Hypoglycemia that has completed, run by Tracey McLaughlin. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02996812, a Phase 1 study of Hyperinsulinemia Hypoglycemia, has completed, sponsored by Tracey McLaughlin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate the safety, efficacy, and pharmacokinetic profile of single ascending doses of exendin 9-39 administered by subcutaneous route in subjects with post-bariatric hypoglycemia.
Primary Outcome
Magnitude of plasma glucose nadir during repeat OGTT after treatment
Conditions Studied
Interventions
- DRUG Exendin (9-39)
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
What the finished NCT02996812 record still lists
NCT02996812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Hyperinsulinemia Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which Exendin (9-39) is the first listed.
NCT02996812 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02996812 about?
NCT02996812 is a clinical study titled "Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia". This study is designed to evaluate the safety, efficacy, and pharmacokinetic profile of single ascending doses of exendin 9-39 administered by subcutaneous route in subjects with post-bariatric hypoglycemia.
What is the current status of trial NCT02996812?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-04. Estimated completion is 2016-08.
What conditions does trial NCT02996812 study?
This clinical trial studies the following conditions: Hyperinsulinemia Hypoglycemia.
What interventions are being tested in trial NCT02996812?
The interventions under investigation include: Exendin (9-39) (DRUG).
Who is sponsoring clinical trial NCT02996812?
This trial is sponsored by Tracey McLaughlin, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02996812 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02996812's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia